An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Fotivda

Chemical Nametivozanib
Dosage FormCapsule (oral; 1.34 mg, 0.89 mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyAVEO Pharmaceuticals, Inc.
Approval Year2021

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Last updated on 3/15/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fotivda (tivozanib) Prescribing Information2021AVEO Pharmaceuticals, Inc. Boston, MA
Document TitleYearSource
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.2020The Lancet. Oncology.